Copy link Copied Copy link Copied Subscribe to gift this article Gift 5 articles to anyone you choose each month when you subscribe. Already a subscriber? Login Beaten-up mining stocks are among the last-minute purchases for Australian fund managers as the year draws to a close and investors scour the market for bargain buys among recent poor performers. The final few months of 2024 have been volatile for the Australian sharemarket. It rose substantially in November following a bullish market reception to Donald Trump’s victory in the US presidential election, only for the S & P/ASX 200 Index to retreat as much as 4 per cent in December. Copy link Copied Copy link Copied Subscribe to gift this article Gift 5 articles to anyone you choose each month when you subscribe. Already a subscriber? Login Introducing your Newsfeed Follow the topics, people and companies that matter to you. Latest In Equity markets Fetching latest articles Most Viewed In Markets
No. 3 Iowa State, Colorado clash in Big 12 opener
LIVERPOOL, England : Liverpool came back after conceding early to beat Leicester City 3-1 at Anfield on Thursday and open a seven-point lead at the top of the Premier League. Struggling Leicester took a shock sixth minute lead through Jordan Ayew but lived a charmed life until Cody Gakpo equalised on the stroke of halftime. Liverpool then put Leicester under siege straight from the break and took just four minutes into the second half to go ahead through Curtis Jones before Mohamed Salah made sure of the points with a superb 82nd-minute finish. The victory extended their unbeaten league run to 13 games and advanced Liverpool to 42 points at the top of the standings. (Writing by Mark Gleeson in Cape Town; Editing by Christian Radnedge)Defensive captain heading toward sad ending to Jets' tenure | Sporting News
None
Ajyal Talk highlights ability of art to nurture social changeA look back at 2024 in photos
NoneA look at crucial role of regulators in power sector
SUZHOU, China , Dec. 30, 2024 /PRNewswire/ -- Hangzhou Sino-US Huadong Medicine Co., Ltd. (hereinafter referred to as " Huadong Medicine "), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), and SynerK PharmaTech (Suzhou) Co., Ltd. (hereinafter referred to as "SynerK") have reached a strategic cooperation. The two parties will jointly develop the small nucleic acid (siRNA) drug SNK-2726, targeting angiotensinogen (AGT) for the treatment of hypertension. Huadong Medicine has obtained the exclusive option, once exercised, for the right to develop, register, manufacture and commercialize the drug in Greate r China. SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage. According to the agreement, the two parties will jointly develop SNK-2726 to a certain stage. At the same time, Huadong Medicine obtains the exclusive option and may pay the exercise fee in the future to obtain the rights for exclusive development, registration, production and commercialization of SNK-2726 in Greater China . After Huadong Medicine exercises its rights, SynerK will also be entitled to receive subsequent R&D milestones and sales milestones, as well as tiered loyalties based on net sales after commercialization. Dr. Tao Lan, CEO of SynerK, said: "We are very excited about the opportunity to cooperate with Huadong Medicine . Huadong Medicine's corporate philosophy of 'scientific research-based and patient-centered' coincides with our mission of 'changing patients' lives.' This cooperation further demonstrates the potential of SynerK's GalNexus siRNA platform. Through this 1+1>2 collaborative effort, we expect to accelerate the development of SNK-2726 and bring new treatment options to patients." Lv Liang, chairman and general manager of Huadong Medicine , said: "We are very pleased to reach this strategic cooperation with SynerK to develop the innovative siRNA drug SNK-2726 together. SynerK has novel nucleic acid drug technology platforms with independent intellectual property rights. Huadong Medicine will use its deep accumulation in innovative drug research and development and rich experience in clinical and commercialization of drugs in the cardiovascular field. Through close cooperation with SynerK, we will jointly accelerate the development of SNK-2726 and benefit more hypertensive patients as soon as possible." About SNK-2726 SNK-2726, with independent intellectual property rights owned by SynerK, is a subcutaneous RNAi drug targeting angiotensinogen (AGT). It is being developed for the treatment of hypertension and is currently in the IND application preparation stage. AGT is the upstream precursor in the renin-angiotensin-aldosterone system (RAAS). AGT in the blood circulation is produced mainly by the liver. Inhibiting the production of AGT can effectively block the activity of the RAAS system and reduce blood pressure. Preclinical study results showed that SNK-2726 can potently inhibit the synthesis of AGT in the liver and has prolonged effects, which can lead to a stable and continuous decrease of AGT, and ultimately lower blood pressure. About SynerK SynerK is a biopharmaceutical company focusing on the development of RNA-targeted therapies. It operates in the USA ( Boston, MA ) and China (Suzhou and Beijing ). The cofounders are industry experts with rich experience in nucleic acid drug discovery and development. SynerK aims to build a world-class RNA-targeted therapeutic company by developing products that have the potential to be first-in-class or best-in-class treatments, targeting diseases that are difficult to cure with existing therapies. For more information, please visit: www.synerk.cn About Huadong Medicine Co., Ltd. Huadong Medicine Co., Ltd. (stock code: 000963.SZ) was founded in 1993 and is headquartered in Hangzhou , Zhejiang . The company adheres to the corporate philosophy of " scientific research-based and patient-centered." After more than 30 years of development, the company's business covers the entire pharmaceutical industry chain, with four major business segments: pharmaceutical industry, pharmaceutical business, aesthetic medicine, and industrial microbiology. It has developed into a listed, large-scale comprehensive pharmaceutical company integrating innovative pharmaceutical research and development, production, and distribution. In 2023, the company achieved operating income of 40.624 billion yuan , with more than 10,000 employees, and has extensive commercial coverage and marketing capabilities. For more information, please visit www.eastchinapharm.com SOURCE SynerKDENVER--(BUSINESS WIRE)--Dec 6, 2024-- Palantir and Anduril, two leading companies at the intersection of commercial technology and national security, are launching a new consortium to ensure that the U.S. government leads the world in artificial intelligence. Our goal is to deliver the technological infrastructure, from the edge to the enterprise, that can enable our government and industry partners to transform America’s world-leading AI advancements into next-generation military and national security capabilities. This partnership is focused on solving two main problems that limit the adoption of AI for national security purposes. The first is data readiness. Most useful national security data— government data that are collected and created by sensors, vehicles, weapons, and robots at the tactical edge—are not retained for AI training and algorithm development. Exabytes of defense data, indispensable for AI training and inferencing, are currently evaporating. What should be America’s ultimate asymmetric advantage over our adversaries is instead our biggest lost opportunity. To solve this, we will utilize Anduril’s Lattice software system and the Anduril Menace family of deployable compute and communications systems to instrument the tactical edge for the government’s secure, large-scale data retention and distribution. Lattice connects directly with third-party defense systems at the edge, delivers autonomy to machine operations, securely distributes their information across a large-scale data mesh, and backhauls all tactical data into government enclaves for the purposes of AI training and inferencing. Menace devices are also purpose-built for the tactical edge, customized down to the silicon level for the unique requirements of national security operations in tactical environments—including, soon, next- generation encryption. The second problem that we seek to solve exists when processing data at scale. Even with national security data that are retained, no secure enterprise pipeline exists to turn that data into AI capabilities. U.S. companies are developing world-leading models but struggling to deploy them at scale with government partners for defense applications. To solve that, we will utilize Palantir’s AI Platform (AIP) to deliver a cloud-based data management and AI development capability that operates at the hyper-scale of commercial industry while meeting the unique requirements of national security. This will enable the structuring, labeling, and preparation of defense data for AI training and development at all levels of classification, including Secure Compartmented Information (SCI) and Special Access Programs (SAP). Palantir’s AIP provides a seamless interface for commercial and government AI developers to conduct imitation and reinforcement learning. It also provides a secure pipeline to deploy, retrain, and redeploy those AI models onto national security systems—a process made even easier, faster, and more reliable through the integration with Anduril’s unique edge capabilities. We will also provide a rapid and ready mechanism to operationalize these new AI capabilities directly through defense production programs that are already fielded. Maven Smart System, powered by the Palantir Platform, provides an enterprise mission command platform that integrates large-scale operational data and utilizes AI-based capabilities to improve and accelerate human decision-making across joint missions, such as intelligence and fires. Similarly, Anduril’s Lattice software platform provides an edge-based mission autonomy platform that integrates directly with robotic systems and utilizes AI-based capabilities to automate and orchestrate their conduct of joint missions, such as air defense and reconnaissance. Anduril and Palantir are joining these complementary systems together, providing a seamless operational capability from the edge to the enterprise that serves as a deployment platform for new AI applications that anyone can build. This platform is already in place and in use by Anduril and Palantir for their own corporate purposes and with government contracts that enables this work to begin immediately. Ultimately, Palantir and Anduril expect to expand the partnership to other industry partners that have unique contributions to make to this unique mission. No single company is capable of delivering on the promise of AI for national security. It takes a team of companies that are willing and able to ensure that the U.S. government remains the world leader in fielding advanced technologies that keep our citizens safe. About Anduril Anduril Industries is a defense technology company with a mission to transform U.S. and allied military capabilities with advanced technology. By bringing the expertise, technology, and business model of the 21st century’s most innovative companies to the defense industry, Anduril is changing how military systems are designed, built and sold. Anduril’s family of systems is powered by Lattice, an AI software platform that turns thousands of data streams into a realtime, 3D command and control center. As the world enters an era of strategic competition, Anduril is committed to bringing cutting-edge AI, computer vision, sensor fusion, and networking technology to the military in months, not years. For more information, visit www.anduril.com. About Palantir Technologies Inc. Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir or management’s expectations regarding the timing and benefits of the transfer of its common stock listing to Nasdaq, including Palantir’s potential eligibility or inclusion in market indices, which cannot be predicted or quantified with certainty. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Additional information regarding these risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise. View source version on businesswire.com : https://www.businesswire.com/news/home/20241206684306/en/ CONTACT: Palantir Contact: media@palantir.comAnduril Contact: Media@anduril.com KEYWORD: COLORADO UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: TECHNOLOGY SECURITY PROFESSIONAL SERVICES PUBLIC POLICY/GOVERNMENT SOFTWARE INTERNET WHITE HOUSE/FEDERAL GOVERNMENT DATA ANALYTICS DATA MANAGEMENT ARTIFICIAL INTELLIGENCE SOURCE: Palantir Technologies Inc. Copyright Business Wire 2024. PUB: 12/06/2024 05:00 PM/DISC: 12/06/2024 05:02 PM http://www.businesswire.com/news/home/20241206684306/en